Contrasting BR Biopharma (BRBI) and Its Competitors

BR Biopharma (NASDAQ:BRBI) is one of 1,749 public companies in the “Capital Markets” industry, but how does it contrast to its competitors? We will compare BR Biopharma to related businesses based on the strength of its institutional ownership, dividends, valuation, earnings, profitability, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent recommendations and price targets for BR Biopharma and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BR Biopharma	1	0	0	0	1.00
BR Biopharma Competitors	5360	19691	21891	612	2.37

As a group, “Capital Markets” companies have a potential upside of 24.89%. Given BR Biopharma’s competitors stronger consensus rating and higher possible upside, analysts plainly believe BR Biopharma has less favorable growth aspects than its competitors.

Earnings & Valuation

This table compares BR Biopharma and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BR Biopharma	$2.23 billion	$31.36 million	138.65
BR Biopharma Competitors	$29.07 billion	$396.20 million	9.77

BR Biopharma’s competitors have higher revenue and earnings than BR Biopharma. BR Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

30.5% of shares of all “Capital Markets” companies are held by institutional investors. 29.4% of BR Biopharma shares are held by company insiders. Comparatively, 13.0% of shares of all “Capital Markets” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Dividends

BR Biopharma pays an annual dividend of $0.42 per share and has a dividend yield of 3.8%. BR Biopharma pays out 525.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. As a group, “Capital Markets” companies pay a dividend yield of 3.1% and pay out 30.8% of their earnings in the form of a dividend.

Profitability

This table compares BR Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BR Biopharma	N/A	N/A	N/A
BR Biopharma Competitors	267.03%	78.17%	3.54%

Summary

BR Biopharma competitors beat BR Biopharma on 11 of the 14 factors compared.

About BR Biopharma

BRBI BR Partners S.A., through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners S.A. is based in S?o Paulo, Brazil.